HPTN Studies

Our studies strive to prevent HIV acquisition and transmission through the use of antiretroviral drugs, interventions for substance use, behavioral risk reduction, and structural interventions. 

HPTN research studies are developed by protocol teams that include CTU investigators and recognized experts in HIV prevention. As study protocols are developed, they undergo a rigorous intra- and extra-Network review process that ensures compliance with current ethical guidelines and regulatory procedures. Each Study Protocol is available once version 1.0 is approved and distributed to the performance sites.

 

Study Snapshot

Study Timelines

Filter studies by:

HPTN 084 (38070)

A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women.

Closed to Accrual

PrEP

HVTN 704/HPTN 085 (30095)

A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men.

Concluded

Antibody Mediated Prevention

HPTN 083 (20725)

Phase 3 study of Cabotegravir LA vs daily oral TDF/FTC for PrEP in HIV uninfected men who have sex with men

Participants Off Study and Primary Analysis Completed

PrEP

HPTN 082 (12068)

Evaluation of Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study

Concluded

PrEP

HVTN 703/HPTN 081 (12045)

A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa.

Concluded

Antibody Mediated Prevention

HPTN 078 (11995)

Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States

Concluded

Integrated Strategy

HPTN 077 (11964)

A Phase IIa Safety, Tolerability and Acceptability Study of an Investigational Injectable HIV Integrase Inhibitor, GSK1265744, for PrEP in HIV Uninfected Men and Women

Concluded

PrEP

HPTN 076 (11944)

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP)

Concluded

PrEP